at2

Buloxibutid (AT2 receptor agonist C21) is a novel and selective small molecule angiotensin II AT2 receptor agonist, exhibiting Ki values of 0.4 nM and 10 μM for AT2 and AT1 receptors, respectively.

MAT2A inhibitor 2 is an inhibitor of methionine adenosyltransferase 2A (MAT2A).

EAAT2 activator 1 (3-[(2-Chloro-6-fluorobenzyl)thio]-6-pyridin-2-ylpyridazine) is a thiopyridazine derivative that has been found to increase EAAT2 protein levels in astrocytes.

MAT2A inhibitor 4 is an inhibitor of the catalytic subunit of methionine S-adenosyltransferase-2, which is used in cancer research.

Novokinin acetate exhibited an affinity for the AT2 receptor with Ki of 7 nM, and its antihypertensive and vasorelaxing activities were blocked by PD123319, an AT2 receptor antagonist.

CGP-42112 acetate is a potent angiotensin receptor AT2 agonist that inhibits the increase in protein kinase A activity produced by LPS.

AT2R antagonist 1 is a highly selective and potent AT2R (angiotensin II AT2 receptor) ligand.AT2R antagonist 1 has a high affinity for AT2R affinity (Ki: 29 nM).AT2R antagonist 1 inhibits common drug metabolizing CYP enzymes and has high stability in human, rat, and mouse liver microsomes.AT2R antagonist 1 has a high affinity for AT2R affinity (Ki: 29 nM).AT2R antagonist 1 has a high affinity for AT2R affinity (Ki: 29 nM). It has high stability in human, rat and mouse liver microsomes.

JNJ-DGAT2-B is a selective inhibitor of Diacylglycerol acyltransferase 2.

MAT2A-IN-9, a 2-oxoquinazoline derivative, is a potent MAT2A (methionine adenylyltransferase 2A) inhibitor.MAT2A-IN-9 has antitumor activity for the treatment of lymphomas and solid tumors.

GAT229 is a positive allosteric modulator of cannabinoid receptor 1 (CB1) and the S-(-) enantiomer of the CB1 modulator GAT211. It does not activate the receptor on its own but enhances the binding and activity of CB agonists. GAT229 (1 μM) enhances the binding of the CB1 full agonist CP 55,940 to CHO cells expressing human recombinant CB1 (hCB1), as well as the activity of 2-arachidonoyl glycerol , arachidonoyl ethanolamide , and CP 55,940 in arrestin2 recruitment assays and increases ERK1/2 and PLCβ3 phosphorylation in HEK293 cells expressing hCB1. GAT229 (1 μM) enhances depolarization-induced suppression of excitation but does not inhibit excitatory postsynaptic currents (EPSCs) in murine autaptic hippocampal neurons. GAT229 (0.2%, topical) reduces intraocular pressure by 5.8 and 7.7 mm Hg after 6 and 12 hours, respectively, in a transgenic mouse model of ocular hypertension using nose, ear, eye mutation (nee) mice.

MAT2A-IN-7, a potent inhibitor of the enzyme MAT2A, demonstrates efficacy in targeting the abnormally elevated expression of MAT2A observed in gastric, colon, liver, and pancreatic cancers. Furthermore, MAT2A-IN-7 effectively reduces the proliferative activity specifically in MTAP-deficient cancer cells, thus highlighting its potential for cancer research applications [1].

MAT2A-IN-4 can be used for the cancer research that is an inhibitor of methionine adenosyltransferase 2A (MAT2A)[1].

GAT211 (AZ-4) is a selective and potent cannabinoid 1 receptor (CB1R) orthosteric modulator (PAM) with high affinity for cAMP and β-arrestin2.GAT211 has IOP-lowering and antipsychotic effects and can be used in the study of epilepsy.

MAT2A-IN-6 is a potent inhibitor of MAT2A that reduces the proliferative activity of MTAP-deficient cancer cells, demonstrating significant research potential in cancer diseases.

NAT2-IN-1 (APA) is a selective inhibitor of the drug metabolism enzyme N-acetyltransferase 2 (NAT2), effectively targeting and eliminating cells with reduced NAT2 activity [1].

MGAT2-IN-4 (compound 33) is a monoacylglycerol acyltransferase 2 (MGAT2) inhibitor with liver metabolic stability, applicable in obesity, diabetes, and non-alcoholic steatohepatitis (NASH) research [1].

MAT2A-IN-3, a potent MAT2A inhibitor, suppresses the proliferative activity of MTAP-deficient cancer cells and shows potential for cancer research [3=c₁(c(c(c(c(c₁cl)O)O)O)I)c₂c(NC(c(n₂)C(F)(F)F)Cl)=O].

MAT2A Allosteric Inhibitor 2 is a potent, selective inhibitor exhibiting an IC50 of 5 nM and demonstrates nanomolar efficacy (IC50 = 5 μM) in proliferation assays utilizing the MTAP -/- cell line [1].

MGAT2-IN-1 is an orally active monoacylglycerol acyltransferase (MGAT2)inhibitor (human and mouse MGAT2 with IC50 of 7.8 and 2.4 nM , respectively).

MAT2A inhibitor 3 can be used in the cancer research. MAT2A inhibitor 3 is a inhibitor of methionine adenosyltransferase 2A (MAT2A) with an IC 50 of <200 nM [1].

GAT228, an allosteric ligand for the cannabinoid receptor 1 (CB1), functions as the enantiomer of GAT211 [1].

VMAT2-IN-2 tosylate is a potent inhibitor of VMAT2, applicable in tardive dyskinesia research [1].

MAT2A-IN-10 (Compound 28), an orally active inhibitor of MAT2A, exhibits an IC50 of 26 nM and is utilized in cancer research [1].

MAT2A Allosteric Inhibitor 1, also known as Compound 5, is a selective inhibitor of methionine adenosyltransferase (MAT) demonstrating potent activity with an IC50 value of 6.8 nM [1].

VMAT2-IN-I HCl is an inhibitor of vesicular monoamine transporter-2. It also has 15- fold greater affinity than GZ- 793A.

MAT2A inhibitor 1 is an inhibitor of methionine adenosyltransferase 2A (MATA2) (IC50 < l00 nM).

JNJ-DGAT2-A, a specific inhibitor of DGAT2(IC50 = 0.14 μM), can be used in studies about the synthesis of triglycerides.

MAT2A-IN-2, a potent inhibitor of MAT2A, shows potential for cancer disease research.

MAT2A-IN-1 is a potent inhibitor of MAT2A, displaying proliferative activity in MTAP-deficient cancer cells. MAT2A is highly expressed in several tumours, including gastric, colon, liver, and pancreatic cancers. MAT2A-IN-1 shows significant potential for cancer research.

MAT2A-IN-8 is an inhibitor of MAT2A.

MAT2A-IN-5, a potent inhibitor of MAT2A, effectively targets the abnormally elevated expression of MAT2A found in various tumor types such as gastric, colon, liver, and pancreatic cancers. By reducing the proliferative activity of MTAP-deficient cancer cells, MAT2A-IN-5 exhibits potential in cancer research applications [1].

MGAT2-IN-2 is a potent inhibitor of acyl CoA:monoacylglycerol acyltransferase 2 (MGAT2) with an IC50 of 3.4 nM.

PD 123319 ((S)-(+)-PD 123319) is a potent, selective AT2 angiotensin II receptor antagonist.

BIBS 39 is a novel nonpeptide angiotensin II (AII) receptor antagonist.

Angiotensin AT2 receptor agonist

Angiotensin III is an agonist of angiotensin 1 (AT1) and AT2 receptor.

Tasosartan (WAY-ANA 756) is an antagonist of angiotensin II type 2 (AT2) receptor (IC50 = 1.2 nM).

Angiotensin III TFA is an agonist of angiotensin 1 (AT1) and AT2 receptor.

CGP-42112 is an agonist of the Angiotensin-II subtype 2 receptor (AT2 R).

Loratadine (SCH 29851) is a second-generation histamine H1 receptor antagonist used in the treatment of allergic rhinitis and urticaria. Unlike most classical antihistamines (HISTAMINE H1 ANTAGONISTS) it lacks central nervous system depressing effects such as drowsiness.

Acroteben is a bio-active chemical. Detailed information has not been published.

Androgen receptor antagonist 4 (Compound AT2) exhibits anticancer activities by potently antagonizing AR transcriptional activity, inhibiting downstream AR target genes, and blocking DHT-induced nuclear translocation of AR. It is an antagonist of the androgen receptor (AR) with an IC50 of 0.15 μM [1].

PD 123319 (ditrifluoroacetate) is a potent and selective AT2 angiotensin II receptor antagonist with an IC50 of 34 nM.

Novokinin TFA is a peptide agonist of the angiotensin (AT2) receptor.